128 related articles for article (PubMed ID: 31735682)
1. [When to introduce hormone therapy after total prostatectomy with positive lymph nodes? Study of the factors influencing the time of introduction of hormone therapy].
Duquesne I; Champy C; Klap J; Chahwan C; Vordos D; de la Taille A; Salomon L
Prog Urol; 2019 Dec; 29(16):981-988. PubMed ID: 31735682
[TBL] [Abstract][Full Text] [Related]
2. [Long-term outcomes of prostate cancer patients with lymph nodes metastasis after radical prostatectomy and pelvic lymph node dissection].
De Vergie S; Gaschignard N; Baron M; Branchereau J; Luyckx F; Butel T; Perrouin-Verbe MA; Bouchot O; Rigaud J
Prog Urol; 2018 Jan; 28(1):25-31. PubMed ID: 29221663
[TBL] [Abstract][Full Text] [Related]
3. Mid-term oncologic outcomes of radical prostatectomy in lymph node metastatic prostate cancer patients.
Berchiche W; Long Depaquit T; Baboudjian M; Barret É; Rozet F; Cathelineau X; Bastide C
Prog Urol; 2023 Aug; 33(8-9):437-445. PubMed ID: 37248105
[TBL] [Abstract][Full Text] [Related]
4. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
5. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
[TBL] [Abstract][Full Text] [Related]
6. Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy.
von Bodman C; Godoy G; Chade DC; Cronin A; Tafe LJ; Fine SW; Laudone V; Scardino PT; Eastham JA
J Urol; 2010 Jul; 184(1):143-8. PubMed ID: 20478587
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of immediate androgen deprivation adjuvant therapy in patients with lymph node positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy].
Miyamae K; Kitani K; Miyamoto K; Hamada S; Kawano T; Maehara A; Otsuka Y; Otsuka T; Hamada Y
Nihon Hinyokika Gakkai Zasshi; 2009 Jul; 100(5):570-5. PubMed ID: 19663244
[TBL] [Abstract][Full Text] [Related]
8. Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study.
Preisser F; van den Bergh RCN; Gandaglia G; Ost P; Surcel CI; Sooriakumaran P; Montorsi F; Graefen M; van der Poel H; de la Taille A; Briganti A; Salomon L; Ploussard G; Tilki D;
J Urol; 2020 Feb; 203(2):338-343. PubMed ID: 31437119
[TBL] [Abstract][Full Text] [Related]
9. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.
Heidenreich A; Fossati N; Pfister D; Suardi N; Montorsi F; Shariat S; Grubmüller B; Gandaglia G; Briganti A; Karnes RJ
Eur Urol Oncol; 2018 May; 1(1):46-53. PubMed ID: 31100228
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Treatment Approaches after Radical Prostatectomy with Lymph Node Involvement.
Tavukçu HH; Erbatu O; Akdoğan B; İzol V; Yücetaş U; Sözen S; Aslan G; Şahin B; Tinay İ; Müezzinoğlu T; Baltacı S
Asian Pac J Cancer Prev; 2022 Jul; 23(7):2279-2284. PubMed ID: 35901332
[TBL] [Abstract][Full Text] [Related]
11. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion.
Preisser F; Bandini M; Marchioni M; Nazzani S; Tian Z; Pompe RS; Fossati N; Briganti A; Saad F; Shariat SF; Heinzer H; Huland H; Graefen M; Tilki D; Karakiewicz PI
Prostate; 2018 May; 78(6):469-475. PubMed ID: 29460290
[TBL] [Abstract][Full Text] [Related]
12. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy.
Briganti A; Karnes JR; Da Pozzo LF; Cozzarini C; Gallina A; Suardi N; Bianchi M; Freschi M; Doglioni C; Fazio F; Rigatti P; Montorsi F; Blute ML
Eur Urol; 2009 Feb; 55(2):261-70. PubMed ID: 18838212
[TBL] [Abstract][Full Text] [Related]
13. [Outcome after radical prostatectomy with extended pelvic lymphadenectomy for untreated high-risk clinically localized prostate cancer].
Tsurusaki T; Yamasaki Y; Maruta S
Nihon Hinyokika Gakkai Zasshi; 2013 May; 104(3):496-504. PubMed ID: 23819361
[TBL] [Abstract][Full Text] [Related]
14. Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes.
Gandaglia G; Soligo M; Battaglia A; Muilwijk T; Robesti D; Mazzone E; Barletta F; Fossati N; Moschini M; Bandini M; Joniau S; Karnes RJ; Montorsi F; Briganti A
Eur Urol; 2019 May; 75(5):817-825. PubMed ID: 30409676
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
[TBL] [Abstract][Full Text] [Related]
16. Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review.
Marra G; Valerio M; Heidegger I; Tsaur I; Mathieu R; Ceci F; Ploussard G; van den Bergh RCN; Kretschmer A; Thibault C; Ost P; Tilki D; Kasivisvanathan V; Moschini M; Sanchez-Salas R; Gontero P; Karnes RJ; Montorsi F; Gandaglia G;
Eur Urol Oncol; 2020 Oct; 3(5):565-581. PubMed ID: 32933887
[TBL] [Abstract][Full Text] [Related]
17. Risk of prostate carcinoma death in patients with lymph node metastasis.
Cheng L; Zincke H; Blute ML; Bergstralh EJ; Scherer B; Bostwick DG
Cancer; 2001 Jan; 91(1):66-73. PubMed ID: 11148561
[TBL] [Abstract][Full Text] [Related]
18. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results.
Daneshmand S; Quek ML; Stein JP; Lieskovsky G; Cai J; Pinski J; Skinner EC; Skinner DG
J Urol; 2004 Dec; 172(6 Pt 1):2252-5. PubMed ID: 15538242
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy.
Touijer KA; Mazzola CR; Sjoberg DD; Scardino PT; Eastham JA
Eur Urol; 2014 Jan; 65(1):20-5. PubMed ID: 23619390
[TBL] [Abstract][Full Text] [Related]
20. Long-term PSA-free survival and castration-free survival with delayed antiandrogen therapy in patients with one versus two or more positive nodes at prostatectomy.
Lodde M; Lacombe L; Naselli A; Puppo P; Mian M; Fradet Y
World J Urol; 2013 Apr; 31(2):293-7. PubMed ID: 22270262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
